The Mayo Clinic Cancer Center (MCCC) Pharmacy Shared Resource (PSR) provides comprehensive pharmacy services in support of 358 open therapeutic clinical trials and 440 studies closed to enrollment with ongoing activity at Mayo Clinic sites in Arizona, Florida and Rochester. The PSR provides pharmacy services exclusively to MCCC members supporting the Clinical Research Programs. The Services of the PSR are essential for protocol development, protocol initiation, and patient treatment on clinical trials. Services include drug procurement, drug storage, and drug accountability of investigational agents assigned to the clinical trials. The PSR is responsible for the preparation and/or sterile admixture of cytotoxic chemotherapy, biotherapy (including targeted, virus/gene therapies, and immunomodulatory therapies), anti-emetics and supportive care medications. The PSR assists the MCCC Clinical Research Office (CRO) in protocol development by providing review and authorship of key sections in each protocol in development including treatment, dose modifications, supportive care, drug-drug interactions and drug monograph sections. The PSR is working on ~130 protocols currently in development. PSR pharmacists also conduct comprehensive medication management consultations (MTM, electronic and in person) for MCCC patients registered to clinical trials to assess eligibility, potential drug-drug interactions, appropriate alternative medications, and proper dosing of medications. PSR pharmacists provide patient counseling for home-going oral investigational medications. The PSR staff has expertise in investigational and commercially available cancer therapeutics ensuring a uniformly high standard of safe and accurate treatment for all MCCC patients. The PSR director has 20 years of experience in pharmacy with 18 years focused in hematology and oncology with extensive involvement in outside organizations promoting the role of the pharmacist in the care of the cancer patient. For the current grant cycle, 147 MCCC members from 8 Programs used PSR services. Prior implementation of Mayo-wide policies and procedures ensure that the PSR remains consistent with guidelines from the Food and Drug Administration, National Cancer Institute, Investigational Review Board, American Society of Health Systems Pharmacy, American College of Clinical Pharmacy, Hematology Oncology Pharmacy Association, State Boards of Pharmacy, the United States Pharmacopeia (USP) and The Joint Commission. The PSR ensures regulatory compliance and provides a uniform level of safe, high quality pharmaceutical care to all MCCC patients enrolled on clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153

Showing the most recent 10 out of 1129 publications